Non-invasive respiratory support strategies in COVID-19
- PMID: 33872588
- PMCID: PMC8051928
- DOI: 10.1016/S2213-2600(21)00168-5
Non-invasive respiratory support strategies in COVID-19
Conflict of interest statement
All authors are responsible for the conduct and delivery of the RECOVERY-Respiratory Support trial, funded by the National Institute for Health Research (NIHR) and referenced in this Comment. BC reports educational fees from Fisher & Paykel, and her institution receives funds from NIHR for a trial in critically ill patients with acute respiratory failure; she is a Director of Research for the Intensive Care Society. GDP reports grants from the NIHR. DFM reports personal fees from consultancy for GlaxoSmithKline, Boehringer Ingelheim, Bayer, Novartis, and Eli Lilly, and from sitting on a data monitoring and ethics committee for a trial undertaken by Vir Biotechnology. DFM's institution has received grants from several funders for studies in patients with acute respiratory distress syndrome and COVID-19; in addition, he has a patent (US8962032) issued to his institution for a treatment for inflammatory disease. DFM is a Director of Research for the Intensive Care Society and Programme Director of the NIHR Efficacy and Mechanism Evaluation programme.
References
-
- Grieco DL, Menga LS, Cesarano M, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA. 2021 doi: 10.1001/jama.2021.4682. published online March 25. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical